Halozyme outlines ENHANZE royalties exceeding $1B in 2026 while launching a new $1B buyback
Halozyme Therapeutics, Inc. · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $68.14
-5.4% in 3d after detection
Post-detection moves
1h
—
1d
-1.3%
3d
-5.4%
7d
-3.4%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS